3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy: what the pharmacist needs to know
Journal of Pharmacy Practice and Research June 1, 2024 Alexander T. Gallo, Paul B. Fitzgerald
AbstractPurpose of ReviewOn 1 July 2023, the Therapeutic Goods Administration approved 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for the treatment of post‐traumatic stress disorder (PTSD). Accordingly, the purpose of this review is to provide an overview of MDMA and what pharmacists should know as this treatment emerges.Sources of InformationEMBASE, MEDLINE, and CINAHL...